Get started
Oric Pharmaceuticals, Inc.Oric Pharmaceuticals, Inc.Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ORIC chart


Full chart

ORIC upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪874.32 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.81 USD
Net income (FY)
‪−100.70 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪45.95 M‬
Beta (1Y)
2.35

Employees


Employees (FY)
100
Change (1Y)
+14 +16.28%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.01 M‬ USD

About Oric Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Jacob M. Chacko
Headquarters
South San Francisco
Website
oricpharma.com
Founded
2014
FIGI
BBG00BL5SLH5
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ORIC news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ORIC is 12.70 USD — it has increased by 15.26% in the past 24 hours. Watch Oric Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oric Pharmaceuticals, Inc. stocks are traded under the ticker ORIC.
ORIC stock has risen by 5.90% compared to the previous week, the month change is a 43.74% rise, over the last year Oric Pharmaceuticals, Inc. has showed a 3.59% increase.
We've gathered analysts' opinions on Oric Pharmaceuticals, Inc. future price: according to them, ORIC price has a max estimate of 25.00 USD and a min estimate of 13.00 USD. Watch ORIC chart and read a more detailed Oric Pharmaceuticals, Inc. stock forecast: see what analysts think of Oric Pharmaceuticals, Inc. and suggest that you do with its stocks.
ORIC reached its all-time high on Dec 18, 2020 with the price of 40.81 USD, and its all-time low was 2.36 USD and was reached on Nov 4, 2022. View more price dynamics on ORIC chart.
See other stocks reaching their highest and lowest prices.
ORIC stock is 7.61% volatile and has beta coefficient of 2.35. Track Oric Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Oric Pharmaceuticals, Inc. there?
Today Oric Pharmaceuticals, Inc. has the market capitalization of ‪874.33 M‬, it has increased by 3.30% over the last week.
Yes, you can track Oric Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Oric Pharmaceuticals, Inc. is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
ORIC earnings for the last quarter are −0.49 USD per share, whereas the estimation was −0.48 USD resulting in a −2.47% surprise. The estimated earnings for the next quarter are −0.51 USD per share. See more details about Oric Pharmaceuticals, Inc. earnings.
Oric Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ORIC net income for the last quarter is ‪−34.57 M‬ USD, while the quarter before that showed ‪−31.96 M‬ USD of net income which accounts for −8.14% change. Track more Oric Pharmaceuticals, Inc. financial stats to get the full picture.
No, ORIC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 6, 2025, the company has 100.00 employees. See our rating of the largest employees — is Oric Pharmaceuticals, Inc. on this list?
Like other stocks, ORIC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oric Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oric Pharmaceuticals, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oric Pharmaceuticals, Inc. stock shows the buy signal. See more of Oric Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.